JMP Securities Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $81
Author: Benzinga Newsdesk | August 07, 2025 08:36am
JMP Securities analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $79 to $81.